Table 1 Characteristics of enrolled patients
Characteristics | 2016 (N = 123) | 2017 (N = 134) | 2018 (N = 111) |
|---|---|---|---|
Sampling clinics; n (%) | |||
 Wirui urban | 89 (72.4) | 40 (29.9) | 57 (51.4) |
 Town | 34 (27.6) | 94 (70.1) | 54 (49.6) |
Age; n (%) | |||
 0–4 | 2 (1.6) | 5 (3.7) | 3 (2.7) |
 5–9 | 13 (10.6) | 19 (14.2) | 19 (17.1) |
 10–19 | 43 (35) | 55 (41) | 44 (39.6) |
 20–29 | 28 (22.8) | 32 (23.9) | 24 (21.6) |
 30–39 | 15 (12.2) | 9 (6.7) | 8 (7.2) |
 40–49 | 11 (8.9) | 6 (4.5) | 7 (6.3) |
 50 | 9 (7.3) | 7 (5.2) | 5 (4.5) |
 Unknown | 2 (1.6) | 1 (0.7) | 1 (0.9) |
 Average | 23.9 | 19.8 | 20.5 |
Sex; n (%) | |||
 Male | 53 (43.1) | 57 (42.5) | 57 (51.4) |
 Female | 69 (56.1) | 76 (56.7) | 53 (47.7) |
 Unknown | 1 (0.8) | 1 (0.8) | 1 (0.9) |
Pretreatment; n (%) | |||
 Artemether | 3 (2.4) | 4 (3.0) | 5 (4.5) |
 Artemether + lumefantrine | 0 (0) | 2 (1.5) | 1 (0.9) |
 Artemether + lumefantrine + primaquine | 0 (0) | 1 (0.8) | 0 (0) |
 Chloroquine | 2 (1.6) | 5 (3.7) | 3 (2.7) |
 Primaquine | 1 (0.8) | 0 (0) | 0 (0) |
Parasitemia; (%) | |||
 Median (IQR) | 0.14% (0.02%, 0.52%) | 0.33% (0.1%, 0.88%) | 0.12% (0.1%, 0.57%) |
MOI; n | |||
 1 | 98 | 113 | ND |
 2 | 13 | 9 | ND |
 3 | 1 | 0 | ND |
 Mean | 1.13 | 1.07 | ND |